Vertical: HealthcareBase Year: 202515 Sections
Market Size (2025)
$249.56M
Projected (2035)
$515.93M
CAGR (2019–2035)
8.3%
Key Players
10+
This report covers China Hepatitis B Treatment Market with forecasts from 2019 to 2035. 10 key companies are profiled.
The China Hepatitis B Treatment Market market is projected to grow at a CAGR of 8.3% from 2019 to 2035.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The China Hepatitis B Treatment Market is navigating a dynamic landscape shaped by robust drivers, persistent restraints, and promising opportunities. Key drivers propel market expansion, starting with the rise in incidence and prevalence of Hepatitis B, fueled by a large chronic carrier population and ongoing transmission risks in high-endemic regions, which heightens demand for therapeutic interventions. Government initiatives and policies play a pivotal role, as national programs prioritize viral hepatitis control through subsidized vaccination drives, public awareness campaigns, and inclusion in essential medicine lists, fostering broader access to care. Advancements in treatment options further accelerate growth, with innovative antiviral regimens, nucleoside analogs, and interferon therapies offering improved efficacy and resistance profiles, drawing investment from pharmaceutical innovators. Complementing these are developments in growing healthcare infrastructure, where expanding hospital networks, specialized liver centers, and digital health platforms in urban and rural areas enhance delivery of specialized treatments.
However, notable restraints temper this momentum. Low diagnosis and treatment coverage rates persist, particularly in underserved rural provinces, where limited screening infrastructure and awareness gaps result in many cases going undetected or unmanaged. High cost of antiviral medications burdens patients and healthcare systems, restricting uptake despite generic availability, especially for long-term regimens. Side effects and treatment adherence issues compound challenges, as frequent adverse reactions like fatigue, renal toxicity, and virological resistance lead to discontinuation, undermining therapeutic outcomes.
Emerging opportunities offer pathways for market evolution. Expansion of screening and early detection programs, supported by point-of-care diagnostics and community-based initiatives, promises to capture undiagnosed cases and shift focus toward proactive management. The functional cure therapeutics market represents a transformative frontier, with research into immune-modulators, RNA interference agents, and novel capsid inhibitors poised to deliver sustained viral clearance, potentially reshaping treatment paradigms and attracting substantial R&D investment. Overall, these dynamics underscore a market ripe for strategic interventions balancing accessibility with innovation.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2025
Historical Period
2019 – 2024
Forecast Period
2026 – 2035
Primary Interviews
150+
Historical data (2019–2025) and forecast period (2025–2035)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEntry barriers include NMPA regulatory requirements, high R&D costs exceeding $500 million per novel therapeutic, and need for clinical trial infrastructure. However, China's "Healthy China 2030" initiative and accelerated approval pathways for functional cure therapies lower barriers for domestic biotech firms. Successful entries by Amoytop Biotech (Pegbing, 2025) and Jiangsu Hansoh demonstrate that focused R&D overcomes incumbent advantages. NVBP policy compresses margins but expands market access. Foreign multinationals face localization requirements. The functional cure segment presents highest opportunity, with over 130 innovative drugs in development and China's favorable regulatory environment for novel mechanisms. (LOW) Supplier power is constrained by API commoditization and government price controls. The nucleos(t)ide analogue segment faces intense generic competition, with over 20 domestic manufacturers producing bioequivalent versions. API supply chains concentrated in China and India provide multiple sourcing options. However, supplier power increases for specialized inputs in next- generation therapies including siRNA constructs and pegylation technologies. COVID-19 exposed supply chain vulnerabilities, prompting vertical integration. Government-mandated centralized procurement transfers pricing power to institutional purchasers, with NVBP requiring substantial price reductions. For complex biologics, limited manufacturing expertise maintains moderate supplier leverage. (HIGH) Buyer power is exceptionally high due to government-dominated procurement.
The NHSA negotiates for 1.4 billion insured citizens, achieving 50-60% price reductions through NRDL negotiations. NVBP institutionalizes buyer power, requiring 50%+ price cuts while guaranteeing 60-70% hospital volumes to winners. Patients have limited direct purchasing power but influence policy through advocacy. "Double envelope" tendering and DRG payment expansion intensify leverage (MODERATE) Substitution occurs across therapeutic generations. Transition from first-generation nucleos(t)ide analogues to next-generation formulations (TAF, TMF) offers improved safety profiles. TAF captures market share by reducing renal/bone toxicity versus TDF. Functional cure therapies represent significant substitution threat—China's Pegbing approval (2025) established precedent for finite-duration treatments displacing lifelong therapy. Over 30 functional cure candidates in development employ siRNA, antisense oligonucleotides, and immune modulators. Non-pharmaceutical substitutes (traditional Chinese medicine, transplantation) exert limited pressure due to clinical guideline preferences. Expanding "treat-all" strategy shifts patterns toward earlier intervention. (HIGH) Rivalry is intense, with price-based generic competition and innovation-driven differentiation. Gilead commands ~80% TAF share through GSK partnerships; BMS maintains entecavir majority despite patent expiry. Domestic manufacturers (Jiangsu Hansoh, Amoytop, Chia Tai Tianqing) capture volume through NVBP—Hansoh's TMF achieved 587 million RMB 2023 sales. Functional cure segment attracts intense R&D investment, with Ascletis, Brii Biosciences, and Suzhou Ribo competing alongside multinationals.
NVBP intensified price competition: entecavir prices declined 98.61%, hospital sales dropped to 1.5 billion RMB by 2023. Strategies shifted to combination therapy, digital health integration, and localized manufacturing partnerships.
See plans for professionals or small and medium businesses.
Analytical insights on China Hepatitis B Treatment Market covering market dynamics, competitive landscape, and strategic outlook.
The China Hepatitis B Treatment Market market is projected to reach $515.93M by 2035, growing at 8.3% CAGR. The Nucleoside Analogues segment holds the largest share.
Introduction
The China Hepatitis B Treatment Market is navigating a dynamic landscape shaped by robust drivers, persistent restraints, and promising opportunities. Key drivers propel market expansion, starting with the rise in incidence and prevalence of Hepatitis B, fueled by a large chronic carrier population and ongoing transmission risks in high-endemic regions, which heightens demand for therapeutic interventions. Government initiatives and policies play a pivotal role, as national programs prioritize viral hepatitis control through subsidized vaccination drives, public awareness campaigns, and inclusion in essential medicine lists, fostering broader access to care. Advancements in treatment options further accelerate growth, with innovative antiviral regimens, nucleoside analogs, and interferon therapies offering improved efficacy and resistance profiles, drawing investment from pharmaceutical innovators. Complementing these are developments in growing healthcare infrastructure, where expanding hospital networks, specialized liver centers, and digital health platforms in urban and rural areas enhance delivery of specialized treatments.
However, notable restraints temper this momentum. Low diagnosis and treatment coverage rates persist, particularly in underserved rural provinces, where limited screening infrastructure and awareness gaps result in many cases going undetected or unmanaged. High cost of antiviral medications burdens patients and healthcare systems, restricting uptake despite generic availability, especially for long-term regimens. Side effects and treatment adherence issues compound challenges, as frequent adverse reactions like fatigue, renal toxicity, and virological resistance lead to discontinuation, undermining therapeutic outcomes.
Emerging opportunities offer pathways for market evolution. Expansion of screening and early detection programs, supported by point-of-care diagnostics and community-based initiatives, promises to capture undiagnosed cases and shift focus toward proactive management. The functional cure therapeutics market represents a transformative frontier, with research into immune-modulators, RNA interference agents, and novel capsid inhibitors poised to deliver sustained viral clearance, potentially reshaping treatment paradigms and attracting substantial R&D investment. Overall, these dynamics underscore a market ripe for strategic interventions balancing accessibility with innovation.
Rise in Incidence and Prevalence of Hepatitis B
China carries the world's largest burden of hepatitis B virus (HBV) infection, with approximately 75 million people living with chronic HBV, representing nearly one-third of the global total. According to the fourth national serological survey conducted in 2020 and published in The Lancet in 2024, the HBsAg prevalence in China's general population stands at 5.86%, with significant regional variations—the eastern region showing the highest prevalence at 4%.
While vaccination programs have dramatically reduced pediatric infection rates to 0.3% among children under five, the adult population remains heavily affected, with prevalence reaching 7.54% among those aged 30 and above. The WHO Global Hepatitis Report 2024 confirms that China alone accounts for 31.5% of global hepatitis B infections. Despite declining incidence rates among younger cohorts, the sheer size of the infected population—combined with an aging demographic transitioning into higher-risk age brackets ensures sustained demand for treatment and management services. The China CDC reports that acute hepatitis B incidence continues to show declining trends, yet chronic infection management remains critical as approximately 30 million HBV-positive individuals remain unaware of their infection status, creating a substantial latent market for diagnosis and treatment services.
Government Initiatives and Policies
The Chinese government has implemented comprehensive policy frameworks to combat hepatitis B, creating a favorable environment for market expansion. The "Healthy China 2030" initiative explicitly targets hepatitis elimination, with the National Disease Control and Prevention Administration releasing action plans in 2024 aiming to raise antiviral treatment rates for newly reported cases to at least 80% by 2030. The National Health Commission's 2022 guidelines expanded treatment eligibility criteria, lowering ALT initiation thresholds to 30 U/L for males and 19 U/L for females, potentially qualifying 94% of patients with detectable HBV DNA for treatment. The National Volume-Based Procurement (NVBP) policy has been transformative—achieving price reductions of up to 98.61% for tenofovir disoproxil fumarate and 98.50% for entecavir, while increasing procurement volumes by 38 million DDDs. This policy has reduced monthly treatment costs from 1,500 CNY to below 10 CNY, fundamentally improving accessibility. Additionally, the "4+7" centralized procurement program and subsequent national expansions have prioritized hepatitis B medications, ensuring sustained government commitment to treatment accessibility. The 2024-2025 period has seen accelerated policy momentum with the integration of hepatitis B screening into routine healthcare services and expanded insurance coverage for antiviral therapies.
Advancements in Treatment Options
China's hepatitis B treatment landscape has witnessed remarkable innovation, positioning the country at the forefront of functional cure research. In October 2025, China approved Pegbing (developed by Amoytop Biotech), the world's first domestically developed drug targeting functional cure, achieving 31.4% clinical cure rates in combination therapy. The National Medical Products Administration (NMPA) has granted conditional approval to multiple breakthrough therapies including pradefovir mesylate (Xinshumu) in 2024—a liver-targeted nucleotide analog demonstrating comparable efficacy to tenofovir with improved renal and bone safety profiles. The approval of libevitug in January 2026 marked China's first-in-class treatment for hepatitis D virus co-infection, addressing a critical unmet need among the 75 million chronic HBV patients
Chinese pharmaceutical companies are leading global clinical trials for novel therapeutic approaches including antisense oligonucleotides (AHB-137, bepirovirsen), siRNA therapies (xalnesiran, BRII-835), and therapeutic vaccines. The China Center for Drug Evaluation (CDE) has established accelerated approval pathways for hepatitis B functional cure candidates, with over 30 innovative therapies in various stages of clinical development. These advancements represent a paradigm shift from lifelong suppression toward finite-duration curative regimens, fundamentally expanding market potential.
Growing Healthcare Infrastructure
China's healthcare infrastructure expansion provides robust support for hepatitis B service delivery. By the end of 2024, the total number of medical institutions reached 1.09 million (increasing by 22,800 year-on-year), with 38,700 hospitals nationwide. Healthcare personnel expanded to 13 million, with 9.4 million working in hospitals, representing 4.3% year-on-year growth. Total national health expenditure reached 9.09 trillion yuan (approximately $1.27 trillion) in 2024, accounting for 6.7% of GDP, with projections indicating growth to 20.5 trillion yuan by 2030. The hospital bed capacity increased to 7.32 beds per 1,000 people in 2024. Critically, primary and secondary-level hospitals now account for 66.6% of all medical visits, with township health centers and community clinics recording 4 billion visits annually.
This infrastructure expansion facilitates decentralized hepatitis B care delivery, enabling the implementation of "Screening-Diagnosis-Treatment-Management" integrated systems recommended in China's 2025 World Hepatitis Day action plan. The National Healthcare Security Administration reports that basic medical insurance covers over 95% of the population, with innovative drugs expected to account for 60% of drug expenditures by 2030.
Expansion of Screening and Early Detection Programs
The substantial gap between infected and diagnosed populations presents significant market opportunities for screening expansion. China's 2025 World Hepatitis Day theme "Societal Co-governance for Hepatitis Elimination" emphasizes establishing integrated "Screening-Diagnosis-Treatment-Management" systems. Cost-effectiveness analyses demonstrate that universal screening strategies for adults aged 18-70 could prevent 3.46 million liver-related deaths over the next decade.
The government's plan to raise diagnosis rates to 90% by 2030 implies screening approximately 45 million additional individuals annually. Pilot programs in high-prevalence regions like Fujian and Guangdong provinces utilizing "five-test universal screening" models have demonstrated feasibility and cost-effectiveness. The integration of HBV screening into routine medical encounters (prenatal care, surgical pre-assessment, hemodialysis) creates multiple touchpoints for case identification. Furthermore, the development of rapid diagnostic tests and point-of-care technologies enables decentralized screening in primary care and community settings, addressing rural access barriers while creating new market segments for diagnostic manufacturers and service providers.
Functional Cure Therapeutics Market
The emergence of functional cure therapeutics represents a transformative market opportunity distinct from traditional long-term suppression therapy. China's approval of Pegbing in October 2025—the world's first functional cure-oriented therapy—established a precedent for premium-priced curative regimens. With 31.4% of patients achieving sustained HBsAg clearance, this therapeutic class commands significant market potential among the 75 million chronic patients seeking finite-duration treatment. The pipeline includes over 30 candidates in clinical development, with Phase III trials expected for multiple assets by 2026-2028. Modeling studies demonstrate that achieving 80% treatment coverage with functional cure regimens could accelerate HBV elimination by 8 years and prevent 1.98 million deaths
The Chinese Foundation for Hepatitis Prevention and Control emphasizes that clinical cure reduces liver cancer incidence from 15% to 1%, creating compelling value propositions for payers and patients. This paradigm shift from chronic management to curative intervention expands market size through premium pricing, improved compliance, and expanded eligible populations previously excluded from indefinite therapy.
Market factor analysis
PORTER'S FIVE FORCES ANALYSIS
PORTER'S FIVE FORCES Analysis: China Hepatitis B Treatment Market
Threat of New Entrants (Moderate)
Entry barriers include NMPA regulatory requirements, high R&D costs exceeding $500 million per novel therapeutic, and need for clinical trial infrastructure. However, China's "Healthy China 2030" initiative and accelerated approval pathways for functional cure therapies lower barriers for domestic biotech firms. Successful entries by Amoytop Biotech (Pegbing, 2025) and Jiangsu Hansoh demonstrate that focused R&D overcomes incumbent advantages. NVBP policy compresses margins but expands market access. Foreign multinationals face localization requirements. The functional cure segment presents highest opportunity, with over 130 innovative drugs in development and China's favorable regulatory environment for novel mechanisms.
Bargaining Power of Suppliers (Low)
Supplier power is constrained by API commoditization and government price controls. The nucleos(t)ide analogue segment faces intense generic competition, with over 20 domestic manufacturers producing bioequivalent versions. API supply chains concentrated in China and India provide multiple sourcing options. However, supplier power increases for specialized inputs in next-generation therapies including siRNA constructs and pegylation technologies. COVID-19 exposed supply chain vulnerabilities, prompting vertical integration. Government-mandated centralized procurement transfers pricing power to institutional purchasers, with NVBP requiring substantial price reductions. For complex biologics, limited manufacturing expertise maintains moderate supplier leverage.
Bargaining Power of Buyers (High)
Buyer power is exceptionally high due to government-dominated procurement. The NHSA negotiates for 1.4 billion insured citizens, achieving 50-60% price reductions through NRDL negotiations. NVBP institutionalizes buyer power, requiring 50%+ price cuts while guaranteeing 60-70% hospital volumes to winners. Patients have limited direct purchasing power but influence policy through advocacy. "Double envelope" tendering and DRG payment expansion intensify leverage
Threat of Substitutes (Moderate)
Substitution occurs across therapeutic generations. Transition from first-generation nucleos(t)ide analogues to next-generation formulations (TAF, TMF) offers improved safety profiles. TAF captures market share by reducing renal/bone toxicity versus TDF. Functional cure therapies represent significant substitution threat—China's Pegbing approval (2025) established precedent for finite-duration treatments displacing lifelong therapy. Over 30 functional cure candidates in development employ siRNA, antisense oligonucleotides, and immune modulators. Non-pharmaceutical substitutes (traditional Chinese medicine, transplantation) exert limited pressure due to clinical guideline preferences. Expanding "treat-all" strategy shifts patterns toward earlier intervention.
Low Diagnosis and Treatment Coverage Rates
Despite high prevalence, China's hepatitis B diagnosis and treatment cascade reveals significant gaps that constrain market realization. According to the 2020 national serosurvey, only 58.78% of HBV-positive individuals were aware of their infection status, and merely 17.33% received antiviral therapy far below WHO's 2030 targets of 90% diagnosis and 80% treatment coverage. This translates to approximately 30 million undiagnosed individuals and 14 million untreated patients who meet treatment criteria
The Global Hepatitis Elimination Profile 2025 reports that only 6.4% of people with HBV were on treatment as of 2022. These gaps stem from fragmented healthcare delivery, insufficient screening infrastructure, and persistent knowledge deficits among healthcare providers. Modeling studies indicate that without intervention, HBV-related mortality targets will not be met until 2059, with an estimated 9.98 million deaths by 2100. The disparity between disease burden and healthcare response represents a critical market constraint, as pharmaceutical innovations cannot achieve commercial success without parallel improvements in diagnostic and care linkage systems.
High Cost of Antiviral Medications
Despite significant price reductions through national procurement policies, antiviral medication costs remain a substantial barrier to treatment access in China. According to a 2024 systematic review published in the International Journal of Clinical Pharmacy, the availability of anti-HBV drugs in primary healthcare facilities is critically low at only 1.4% for original brands and 1.7% for lowest-priced generics, creating access barriers for rural populations. While the National Volume-Based Procurement (NVBP) policy achieved dramatic price reductions lowering tenofovir disoproxil fumarate (TDF) costs to approximately $12 per person per year and entecavir (ETV) to $17.60 affordability remains problematic. The 2024 study in Jiangsu province revealed that despite favorable pricing (median price ratios below 1.5 times international reference prices), the affordability rate was only 23% for urban residents and 0% for rural residents when accounting for comprehensive treatment costs including monitoring and follow-up care.
The economic burden extends beyond drug acquisition costs. A 2024 analysis of curative care expenditure in Sichuan Province demonstrated that out-of-pocket payment ratios for outpatient services reach 75.71%, significantly higher than the 40.21% for inpatient services, primarily because special outpatient chronic disease reimbursement is limited to 50% of costs with annual caps as low as $361.79. The per capita annual expense for monitoring CHB patients—including routine blood tests, HBV DNA quantification, biochemical tests, and abdominal ultrasound—averages approximately $205.30 according to current secondary hospital charging standards, exceeding the newly introduced outpatient mutual aid insurance policy annual reimbursement limit of $289.44. Furthermore, cost-effectiveness analyses indicate that while generic first-line antivirals are now affordable for many, the threshold price for functional cure therapies remains challenging at $1,744 for patients with cirrhosis and $1,001 for those without cirrhosis, potentially limiting access to curative regimens as they become available.
Side Effects and Treatment Adherence
Long-term antiviral therapy for hepatitis B presents significant adherence challenges due to side effects and the asymptomatic nature of chronic infection. A 2024 meta-analysis published in BMJ Open examining low-level viremia (LLV) in Chinese CHB patients found that poor medication adherence was associated with a 55.9% prevalence of LLV compared to only 27.1% in adherent patients, highlighting the clinical consequences of non-compliance. The study identified that medication adherence affects treatment effectiveness more significantly than specific drug choice, with patients demonstrating poor compliance exhibiting 2.9-fold increased risks of hepatocellular carcinoma and 5.4-fold increased risks of all-cause mortality
Real-world data from 2024-2025 demonstrates that side effects drive treatment discontinuation and switching. A study of treatment-experienced patients switching to tenofovir alafenamide (TAF) revealed that 27.7% switched due to renal tubular injury, 22.3% due to increased creatinine, and 4.3% due to decreased blood phosphorus—toxicities primarily associated with tenofovir disoproxil fumarate (TDF) use. Additionally, 11.7% switched due to low-level viremia, indicating suboptimal viral suppression despite adherence. Gastrointestinal symptoms including nausea and dyspepsia were more frequently reported with TAF compared to entecavir, while skin itching occurred exclusively with ETV therapy.
The psychological burden of lifelong daily medication significantly impacts adherence. A 2025 cross-sectional study at a Shanghai tertiary hospital found that existing literature reports medication adherence rates in CHB patients ranging from 50% to 80%, with the estimated 5-year adherence to oral antiviral therapy approximately 75%. This study confirmed that shared decision-making and patient self-efficacy significantly influence adherence, with patients experiencing better physical functioning demonstrating higher treatment compliance. However, physical symptoms—whether disease-related or treatment-induced—create a paradox where patients may unintentionally miss doses due to fatigue and muscle pain or intentionally avoid medication due to concerns about potential side effects, despite evidence that non-adherence increases risks of viral breakthrough, drug resistance, and hepatic decompensation.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the China Hepatitis B Treatment Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Sanofi is a top-tier global biopharmaceutical company that has, over six years, deliberately narrowed itself from a diversified healthcare conglomerate into a single-segment, R&D-led specialty medicines and vaccines business. Its centre of gravity is immunology: Dupixent, co-developed with Regeneron, generated €15.7bn in FY2025 — 36% of group sales — and management now guides to approximately €25bn by 2030. Around that core sit a differentiated rare-disease franchise (Pompe, Gaucher, Fabry, haemophilia, ASMD), the world's broadest vaccines portfolio outside Merck and GSK, and a smaller oncology and neurology presence. The company shed EUROAPI in 2022 and sold control of Opella consumer health to CD&R in 2025 for €10.4bn net. Financially it is unusually clean — 77.5% business gross margin, 0.8x net debt/EBITDA, 31 consecutive years of dividend increases. The unresolved question, and the reason for a February 2026 CEO change, is whether its internal pipeline can replace Dupixent's eventual erosion. *Caveat: Sanofi does not publish a single headline headcount in its quarterly releases. The FY2021 figure derives from the company's 2022 employee share plan disclosure ("over 90,000 employees in 73 countries" eligible in 2021); the FY2024/FY2025 figure of ~83,000 is the company-sourced number cited in industry reporting at the time of the March 2025 US investment announcement, reflecting both restructuring and the Opella separation. Precise year-end FTE counts are disclosed in the Universal Registration Document / Form 20-F and are not restated here. The 2025 employee share plan was offered to "around 70,000 employees in 55 countries" — an eligibility population, not total headcount.* --- ### What Sanofi does Sanofi researches, develops, manufactures and commercialises prescription medicines and human vaccines. Since January 1, 2025 it reports one operating segment, Biopharma, plus an immaterial "Other" line that captures residual Opella-related transitional revenues and manufacturing services. Sanofi's own characterisation, used verbatim in every 2026 press release, is: *"Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world."* The formal segment description in its 2025 shelf-registration prospectus reads: *"We have one operating segment: Biopharma. It comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises plus support and corporate functions, for all geographical territories."* Internally, and in the reporting taxonomy adopted from FY2025, the business is organised as: - **Pharma** - *Immunology* — Dupixent, Kevzara - *Rare diseases* — Fabrazyme, Cerezyme/Cerdelga, Myozyme/Nexviazyme, Aldurazyme, Xenpozyme, ALTUVIIIO, Eloctate, Alprolix, Cablivi, Qfitlia, Wayrilz, Ayvakit - *Neurology* — Aubagio (in run-off), Cenrifki (tolebrutinib) - *Oncology* — Sarclisa, Jevtana, Fasturtec - *Other main / established medicines* — Lantus, Toujeo, Apidra, Soliqua, Plavix, Lovenox, Aprovel, Multaq, Praluent, Thymoglobulin, Rezurock, Synvisc - **Vaccines** — influenza (Fluzone/Efluelda/Vaxigrip), polio/pertussis/Hib (Pentacel, Pentaxim, Hexaxim, Vaxelis via JV), meningitis (Menactra, MenQuadfi), travel/endemic (rabies, yellow fever, typhoid, hepatitis A), Beyfortus (RSV mAb, with AstraZeneca), Nuvaxovid (COVID-19), Heplisav-B (adult hepatitis B, acquired with Dynavax) ### Revenue model Sanofi's revenue is overwhelmingly product sales of patented and off-patent pharmaceuticals and vaccines — there is effectively no subscription or service revenue. The economics have four distinct layers: 1. **Net sales (€43,626m FY2025)** — gross invoiced product sales less gross-to-net deductions (US rebates, Medicaid/340B, chargebacks, ex-US statutory price cuts, China VBP/NRDL). 2. **Other revenues (€3,090m FY2025)** — a materially different-margin stream comprising VaxServe's distribution of *non-Sanofi* vaccines in the US (€1,780m FY2025, declining), manufacturing services (€557m), transitional sales of Opella products in certain markets (€487m), and royalties (€146m). 3. **Alliance profit-sharing, recorded in other operating income/expenses** — this is the single most important non-obvious feature of Sanofi's P&L. Sanofi books 100% of worldwide Dupixent and Kevzara sales but must then pay Regeneron its share of alliance profit. In FY2025 the total charge related to Regeneron was €4,923m, of which €5,065m was the monoclonal-antibody alliance net (profit/loss share −€5,455m, plus €1,089m of Regeneron's contribution to development costs, less €699m reimbursement of Regeneron commercial operating expenses). This charge grew 28% year-on-year and structurally caps Sanofi's operating leverage on its fastest-growing asset. 4. **Out-licensing royalties** — notably the Amvuttra royalty (€398m in H1 2026, up from €120m in H1 2025) and other license-out income (€495m FY2025). ### Value chain position and customers Sanofi is a fully integrated originator: discovery research, clinical development, regulatory, primary and secondary manufacturing (biologics, sterile injectables, vaccine bulk and fill-finish), and direct commercialisation in most markets. It also operates VaxServe, a US vaccine and specialty-pharmaceutical distribution business that carries third-party product — a rare downstream extension. Customers are institutional rather than retail: US wholesalers (McKesson, Cencora, Cardinal) and PBMs, national and regional health systems and tender authorities in Europe, public immunisation programmes and supranational buyers (UNICEF, PAHO, Gavi) for vaccines, hospital groups, and specialty pharmacies for rare disease and biologic products. End-markets are immunology and inflammation, rare genetic disease, haematology, multiple sclerosis, multiple myeloma, diabetes, cardiovascular disease, and paediatric and adult immunisation. ### Independent characterisation Functionally Sanofi is now one very large product (Dupixent) plus a durable but low-growth annuity book plus an option on a rebuilt pipeline. Dupixent contributed 36% of FY2025 net sales and 44.4% of Q2 2026 net sales, and grew 37.6% in Q2 2026 — meaning group growth is almost entirely one franchise. The vaccines business, historically Sanofi's defensive ballast, has become a source of volatility: it declined 1.2% in FY2025 and 1.1% in H1 2026, pressured by falling birth rates in China, US immunisation-policy uncertainty, and competitive tendering. The rare-disease and haemophilia portfolios are genuinely differentiated but individually sub-scale. The strategic problem management is now addressing is that Sanofi has bought growth (Blueprint, Dynavax, Vicebio) faster than it has generated it internally — and in July 2026 discontinued three of the assets that were supposed to be the answer.
5 interactive charts drawn from the China Hepatitis B Treatment Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
China Hepatitis B Treatment Market By Distribution Channel
China Hepatitis B Treatment Market By Age Group
China Hepatitis B Treatment Market By Route Of Administration
China Hepatitis B Treatment Market By Drug Class
China Hepatitis B Treatment Market
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
